Elicio Therapeutics, Inc. Interest Expense
Elicio Therapeutics, Inc. (ELTX) reported Interest Expense of $36.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-15.
Discontinued › Expense Statement
us-gaap:InterestExpense · last filed 2024-05-15
- Elicio Therapeutics, Inc. interest expense for the quarter ending 2024-03-31 was $36.00K, a 89.47% decline year-over-year.
- Elicio Therapeutics, Inc. interest expense for the quarter ending 2023-12-31 was $2.00K, a 97.83% decline year-over-year.
- Elicio Therapeutics, Inc. interest expense for the quarter ending 2023-09-30 was $1.00K, a 99.91% decline year-over-year.
- Elicio Therapeutics, Inc. interest expense for the quarter ending 2023-06-30 was $714.00K, a 33.08% decline year-over-year.
- Elicio Therapeutics, Inc. interest expense for fiscal 2023 was $1.06M, a 70.56% decline from fiscal 2022.
- Elicio Therapeutics, Inc. interest expense for fiscal 2022 was $3.60M.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2024-03-31 | $36.00K 10-Q · filed 2024-05-15 | $38.00K derived: sum of 2 quarters · filed 2024-05-15 | $39.00K derived: sum of 3 quarters · filed 2024-05-15 | $753.00K derived: sum of 4 quarters · filed 2024-05-15 |
| 2023-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $3.00K derived: sum of 2 quarters · filed 2024-03-29 | $717.00K derived: sum of 3 quarters · filed 2024-03-29 | $1.06M 10-K · filed 2024-03-29 |
| 2023-09-30 | $1.00K 10-Q · filed 2023-11-13 | $715.00K derived: sum of 2 quarters · filed 2023-11-13 | $1.06M 10-Q · filed 2023-11-13 | $1.15M derived: sum of 4 quarters · filed 2024-05-15 |
| 2023-06-30 | $714.00K 10-Q · filed 2023-08-14 | $1.06M 10-Q · filed 2023-08-14 | $1.15M derived: sum of 3 quarters · filed 2024-05-15 | $2.23M derived: sum of 4 quarters · filed 2024-05-15 |
| 2023-03-31 | $342.00K 10-Q · filed 2024-05-15 | $434.00K derived: sum of 2 quarters · filed 2024-05-15 | $1.51M derived: sum of 3 quarters · filed 2024-05-15 | $2.58M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $92.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $1.17M derived: sum of 2 quarters · filed 2024-03-29 | $2.24M derived: sum of 3 quarters · filed 2024-03-29 | $3.60M 10-K · filed 2024-03-29 |
| 2022-09-30 | $1.08M 10-Q · filed 2023-11-13 | $2.15M derived: sum of 2 quarters · filed 2023-11-13 | $3.50M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $1.07M 10-Q · filed 2023-08-14 | $2.43M 10-Q · filed 2023-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |